Limb-Girdle Muscular Dystrophy

Vita Therapeutics Raises $32 Million in Oversubscribed Series A Financing Led by Cambrian Biopharma to Advance the Development of Therapies to Treat Muscular Dystrophies

Retrieved on: 
Wednesday, June 23, 2021
Biotechnology, Other Health, Health, Genetics, Pharmaceutical, Muscular dystrophy, Dystrophy, Genetic engineering, Branches of biology, Limb-Girdle Muscular Dystrophy, Vita Therapeutics, LIMB-GIRDLE MUSCULAR DYSTROPHY, VITA THERAPEUTICS

The financing was led by Cambrian Biopharma with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures.

Key Points: 
  • The financing was led by Cambrian Biopharma with participation from Kiwoom Bio, SCM Life Sciences, and Early Light Ventures.
  • This oversubscribed round of financing will enable the company to take the next steps toward achieving our mission.
  • I am so glad to count Vita as a Cambrian affiliate, and I have no doubt Vita will become a genre-defining cell therapy company.
  • Vitas second therapeutic, VTA-200, is a genetically engineered iPSC derived hypoimmunogenic treatment designed to treat multiple types of muscular dystrophy.